Over the past year, a:head has achieved significant milestones across technology development, scientific innovation, and commercial execution. The company established its first industrial partnerships, secured substantial public funding for the development of an Alzheimer's disease neuroimmune organoid platform, strengthened its Supervisory Board through the appointments of renowned industry experts, and introduced new platform protocols that significantly improve scalability, automation, reproducibility, and cost efficiency.
Over the past year, a:head has achieved significant milestones across technology development, scientific innovation, and commercial execution. The company established its first industrial partnerships, secured substantial public funding for the development of an Alzheimer's disease neuroimmune organoid platform, strengthened its Supervisory Board through the appointments of renowned industry experts, and introduced new platform protocols that significantly improve scalability, automation, reproducibility, and cost efficiency.
"Investors today are looking for more than promising science," said Josh Bagley, CSO of a:head bio AG. "They want evidence of execution. Over the past year, we have improved the scalability and robustness of our platform, established our first industrial partnerships, expanded into neurotoxicology applications, and secured significant external validation. These achievements demonstrate that our technology is moving beyond the laboratory and toward real-world applications in drug discovery and safety assessment."
The financing marks another important milestone in a:head's mission to establish human-relevant brain tissue models as a new standard for neuropharmacology, enabling more reliable prediction of drug efficacy and safety in humans while reducing reliance on models with limited translational value.
About a:head bio AG
a:head bio AG is an Austrian biotechnology company advancing neuropharmacology through a proprietary platform based on scalable human brain organoids. Unlike traditional approaches relying on
molecular targets and animal models, the company recreates central nervous system biology and disease in human brain tissue at scale. By combining cell reprogramming, gene editing, advanced 3D
culture technologies, digital biology, and AI-driven data analysis, a:head develops human-relevant models designed to improve the predictive power of research, development, and safety assessment. The company's platform enables the study of neurological disease, therapeutic response, and neurotoxicity in human tissue systems with unprecedented physiological relevance.
Contact
a:head bio AG
Dr.-Bohr-Gasse 7, VBC6
1030 Vienna, Austria
Oliver Szolar, CEO
oliver.szolar(at)aheadbio.com
+43 1 3660519
www.aheadbio.com